TickerFiles

Amphastar Pharmaceuticals, Inc. 10-K filing

Filed 2026-02-26 · Report date 2025-12-31 · 2025 FY

View Original SEC Filing

Filing metadata

Accession number
0001297184-26-000009
Form type
10-K
CIK
0001297184
Primary document
https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm

Extracted primary information

This filing includes deterministic financial metrics extracted from public filing data for Amphastar Pharmaceuticals, Inc..

Reported financial metrics

MetricCurrentPriorChange
Revenue$719.9M--
Cost Of Revenue$363.8M--
Gross Profit$356.1M--
Operating Income$140.4M--
Net Income$98.1M--
Eps Basic2.1--
Eps Diluted2.03--
Cash And Equivalents$170.2M--
Total Assets$1.6B--
Total Liabilities$840.5M--
Operating Cash Flow$156.1M--
Capital Expenditures$34.9M--